Opinion

Video

Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

Author(s):

Robert Z. Orlowski, MD, PhD,Jonathan L. Kaufman, MD

The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.

Related Videos
Mansi R. Shah, MD
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Anitocabtagene Autoleucel in Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM

Ide-cel in multiple myeloma
December 10th 2024

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma